Interact with your peers.
See what's being published in neurology and the neurosciences.
For the first time a "tipping point" molecular link between the blood sugar glucose and Alzheimer disease has been established by scientists, who have shown that excess glucose damages a vital enzyme involved with inflammation response to the early stages of Alzheimer disease -- MIF (macrophage migration inhibitory factor). The study is published in the journal Scientific Reports.
Postmenopausal estrogen-based hormone therapy lasting longer than 10 years was associated with a decreased risk of Alzheimer disease in a large study carried out at the University of Eastern Finland. The study also found long-term use of hormonal replacement therapy was associated with a better performance in certain cognitive domains, namely global cognition and episodic memory.
Researchers have demonstrated that if an affected parent passes on the C9orf72 mutation, the children will be affected at a younger age than the parent. There are no indications that the disease progresses more quickly. These results are published today in JAMA Neurology.
Print or email information for your patients when needed.
Explore other relevant websites. Close the window to return to MedLink.